Quest Diagnostics Inc (DGX) reported quarterly earnings results on Thursday, Jul-21-2016. The company said it had a profit of $1.34 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $1.32. The company posted revenue of $1906.00 million in the period, compared to analysts expectations of $1905.57 million. The company’s revenue was down -1.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.25 EPS.
Quest Diagnostics Inc opened for trading at $83.5 and hit $83.86 on the upside on Wednesday, eventually ending the session at $83.56, with a gain of 0.49% or 0.41 points. The heightened volatility saw the trading volume jump to 9,64,586 shares. Company has a market cap of $11,820 M.
In a different news, on Jun 1, 2016, Catherine T. Doherty (SVP, Clin. Franchise Solutions) sold 47,334 shares at $77.27 per share price. According to the SEC, on May 16, 2016, Jenne K Britell (director) sold 8,000 shares at $75.68 per share price. On May 11, 2016, Everett Cunningham (SVP, Commercial) sold 56,312 shares at $76.24 per share price, according to the Form-4 filing with the securities and exchange commission.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.